DDD (FINALS ALL TOPICS)

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/64

encourage image

There's no tags or description

Looks like no tags are added yet.

65 Terms

1
New cards

Pharmaceutical Development

  • transforming an Active Pharmaceutical Ingredient into a finished medicinal product suitable for handling, distribution and patient administration


2
New cards

Quality Target Product Profile

  • establishes the ideal dosage form, strength, release profile, shelf-life, and route of administration based on patient needs and biopharmaceutical requirements


3
New cards

Aqueous Solubility

  • key determinant of drug absorption and BA

  • a drug must be in solution to be absorbed


4
New cards

Surface reaction

  • drug molecules detach from the solid into stagnant boundary layer next to it


5
New cards

Mass Transfer

  • molecules diffuse from the boundary layer into the bulk solution


6
New cards

Stability

  • a drug product for routine use is expected to have a shelf-life of at least 3 years presenting less than 5% decomposition and no significant physical change under normal storage conditions


7
New cards

Accelerated Stability Testing

  • Typically exposing formulations to elevated temperatures and relative humidities (such as 40 C/75% RH) for 1 to 4 weeks


8
New cards

Quality by Design

  • Formulation of an active substance into a dosage form involves

    careful designing, using good science and common sense. This

    systematic approach is usually referred


9
New cards

Micelles

  • Lipophilic drugs dissolve in the core, reaching concentrations far above their aqueous solubility


10
New cards

Liposomes

  • Can carry a PEG polymer coat and antibody targeting

    molecules


11
New cards

Nanotechnology

  • Great potential for targeted delivery in cancer and organ-

    specific delivery (e.g.,CNS)


12
New cards

Modified release formulations

  • shorten onset or prolong duration of action

➔ Absorption rate is then set by the release rate from the dosage

form

13
New cards

Sustained Release

  • gradual absorption to reach a steady level for hours or days


14
New cards

Delayed release

  • for oral drugs unstable at the low pH of the stomach


15
New cards

Controlled release

  • specialized devices allow the release rate to be adjusted as needed


16
New cards

Clinical development

  • generate sufficient understanding of safety and efficacy to support marketing authorization


17
New cards

Phase I

  • preliminary understanding of a new medicine’s clinical pharmacology


18
New cards

First-in-Human Studies

  • conducted in healthy volunteers, focused mainly on PK and safety


19
New cards

Single ascending dose

  • 6-10 dose levels, 2+ cohorts; typically 4 active + placebo per cohort


20
New cards

Sentinel dosing

  • one active + one placebo subject dose first and observed before the rest of the cohort


21
New cards

Multiple Ascending dose

  • follows duration informed by half-life, aims to characterize steady-state PK


22
New cards

Linear Kinetics

  • proportional increase in Cmax/AUC with dose


23
New cards

Nonlinear Kinetics

  • disproportionate increase

  • may indicate absorption saturation or reduced clearance


24
New cards

Phase II POC

  • the make or break study for most drugs in development


25
New cards

Phase III

  • principally supports registration; must provide substantial evidence for risk/benefit assessment to support marketing authorization


26
New cards

Thorough OT

  • assesses risk of drug-induced QT prolongation

    (torsades de pointes risk) via regular ECGs at therapeutic/

    supratherapeutic doses


27
New cards

Bioequivalence

  • required if formulation changes – new

    formulation’s exposure must fall within 80-125% of key PK

    parameters vs. origina


28
New cards

Drug Interactions

  • PK or PD mechanisms; drugs as

    “perpetrators” or “victims”; modelling/ simulation increasingly

    predicts which interactions are clinically significant


29
New cards

Phase IV

  • Safety database at registration is typically limited; regulators

    may require post-marketing safety information

  • conducted after authorization– two

categories: regulator required safety studies, and sponsor-

initiated studies extending indications

30
New cards

Phase 0 (microdose)

  • shorter toxicology package (<14

    days); pharmacologically inactive microdose used to establish PK

    properties before committing to full development


31
New cards

Clinical Imaging in Drug Development

  • To provide tools for more direct translation of biological

    understanding from animals to humans


32
New cards

Positron Emission Tomography

  • Uses radiolabeled ligands that bind selectively to a

    biological target


33
New cards

Magnetic Resonance Imaging

  • Relies on the magnetic properties of hydrogen nuclei in the

    body


34
New cards

Structural MRI

  • provides 3D anatomical images of organs

    and tumors



35
New cards

Contrast-enhanced MRI

  • uses agents like Gadolinium to

    highlight blood flow or a disrupted BBB


36
New cards

Functional MRI

  • measures blood oxygenation changes to

    map neuronal activity


37
New cards

Computed Tomography

  • X-ray based method primarily for anatomical screening and

    tumor size monitoring in oncology


38
New cards

PET-CT

  • combining molecular and structural data to reduce

    artifacts and provide better localization


39
New cards

Intellectual Property

  • refers to creations of the mind

  • it can be an invention (patent/utility model), a design (industrial design), a brand name (trademark, or a literary and artistic work)


40
New cards

Patent

  • A grant by a nation state or supranational body of the exclusive right to commercialize an invention in that state for a limited time


41
New cards

Novelty

  • The invention must not have been known to the public anywhere in the world before the filing date (no prior art)


42
New cards

Inventive step

  • the invention must not be obvious to a person skilled in the art (e.g., standard medicinal chemist)


43
New cards

Industrial Applicability

  • The invention must be capable of being made or used in an

    industry


44
New cards

The State of the Art

  • All published material in the technical field up to the relevant

    date


45
New cards

Regulatory Affairs

  • ensures that a pharmaceutical company complies with all regulations governing the development, manufacturing, and marketing of medicinal products


46
New cards

1937 Elixir Sulfanilamide

  • Led to the 1938 US Food, Drug and Cosmetics Act after 107

    people died from toxic solvent ingestion


47
New cards

1961 Thalidomide Disaster

  • Phocomelia

● Note: that these tragedies drugs be proven forced both safe government to mandate and effective before they are sold


48
New cards

Development Phase

➔ Pricing strategy and marketing plans are prepared before

launch.


49
New cards

Introduction

  • This is must where marketing spend is highest and the product must be available in all outlets, such as pharmacies


50
New cards

Direcgt to consumer advertising

  • Direct marketing to patients in print, television and radio, legally

    permitted in only a few countries, such as the US and New

    Zealand


51
New cards

Blockbuster

  • is a drug that generates over 1 billion in anual sales


52
New cards

Target Validation

  • Uses “chemical probes” (imaging ligands) to prove a target’s

    role in a tissue before full drug development.


53
New cards

Biodistribution

  • Confirms the drug reaches the tissue

  • Warning: species differences are common; a drug might penetrate the BBB in rats but not in humans


54
New cards

Target Interaction

  • Measuring receptor occupancy – how much of the target

is “occupied” by drug at different doses.

55
New cards

Pharmacodynamics

  • Measuring the biological response (e.g., FDG-PET to

    measure glucose metabolism in tumors or the brain)


56
New cards

Growth

  • The market accepts the product and market share grows;

    marketing becomes more targete


57
New cards

Maturity

  • The market no longer grows, and this is the most profitable stage


58
New cards

Decline

  • Increased competition and loss of sales and profits,

    generally at the end of patent life


59
New cards

Market dynamics

  • Marketing teams data from standard must assess sources (e.g., the therapeutic IQVIA) to area using identify target

physician segments

60
New cards

Competitor Assessment

  • analyze competitor’s sales volumes, investment levels and promotional messages


61
New cards

Key opinion leaders

  • “Thought leaders” are respected individuals in a therapeutic area,

    such as prominent medical school faculty, who influences physicians through their personal status


62
New cards

Market Access

  • defined as the process of ensuring a medicine is available to patients and funded by health system


63
New cards

Value based pricing

  • Setting a price based on the perceived value of the health

    benefit provided, rather than just the cost of production


64
New cards

International reference pricing

  • governments setting prices by comparing what other countries pay for the same drug


65
New cards

Tendering

  • a competitive process where companies bid to supply a drug to a hospital or health system